Prospective Grant of an Exclusive Patent License: Agonist/Antagonist Compositions and Methods of Use, 61659 [2018-26016]
Download as PDF
<![CDATA[
Federal Register / Vol. 83, No. 231 / Friday, November 30, 2018 / Notices
NIAID, NIH, 40 Convent Drive, Bethesda, MD
20892, (301) 496–1852, jmascola@nih.gov.
Any interested person may file
written comments with the committee
by forwarding the statement to the
Contact Person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: November 26, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–26014 Filed 11–29–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Patent License: Agonist/Antagonist
Compositions and Methods of Use
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Cancer Institute,
an institute of the National Institutes of
Health, Department of Health and
Human Services, is contemplating the
grant of an Exclusive Patent License to
practice the inventions embodied in the
Patents and Patent Applications listed
in the Supplementary Information
section of this notice to Bull Run
Capital, Inc. located in Vancouver, BC,
Canada.
SUMMARY:
Only written comments and/or
applications for a license which are
received by the National Cancer
Institute’s Technology Transfer Center
on or before December 17, 2018 will be
considered.
DATES:
Requests for copies of the
patent application, inquiries, and
comments relating to the contemplated
an Exclusive Patent License should be
directed to: Jaime M. Greene, Senior
Licensing and Patenting Manager, NCI
Technology Transfer Center, 9609
Medical Center Drive, RM 1E530 MSC
9702, Bethesda, MD 20892–9702 (for
business mail), Rockville, MD 20850–
9702; Telephone: (240) 276–5530;
Facsimile: (240) 276–5504; Email:
greenejaime@mail.nih.gov.
amozie on DSK3GDR082PROD with NOTICES1
ADDRESSES:
SUPPLEMENTARY INFORMATION:
VerDate Sep<11>2014
17:00 Nov 29, 2018
Jkt 247001
Intellectual Property
U.S. Provisional Patent Application
No. 61/340,063, filed March 12, 2018,
now abandoned, titled ‘‘Agonist/
Antagonist Compositions and Methods
of Use’’, HHS Ref. No.: E–048–2010–0–
US–01;
PCT Patent Application Serial No.
PCT/US2011/028132, filed March 11,
2011, now abandoned, HHS Reference
Number E–048–2010–0–PCT–02 titled
‘‘Agonist/antagonist compositions and
methods of use’’;
U.S. Patent 9,277,748 (Application
No. 13/634,447) filed March 11, 2011,
issued March 8, 2016, titled ‘‘Agonist/
antagonist compositions and methods of
use’’, HHS Ref. No.: E–048–2010–0–US–
04;
Canada Patent Application Serial No.
2,792,878, filed March 11, 2011, HHS
Reference Number E–048–2010–0–CA–
03 titled ‘‘Agonist/antagonist
compositions and methods of use’’; and
U.S. Patent Application Serial No 15/
010,830, filed January 29, 2016, HHS
Reference Number E–048–2010–0–US–
05, titled ‘‘Agonist/antagonist
compositions and methods of use’’.
The patent rights in these inventions
have been assigned and/or exclusively
licensed to the government of the
United States of America.
The prospective exclusive license
territory may be worldwide and the
field of use may be limited to: ‘‘Use of
the TRVP1 antagonists BCTC,
AMG9810, JYL–827, Capsazepine or
IodoRTX combined with a TRVP1
agonist in a composition for the
temporary incapacitation of a subject.’’
This technology discloses novel
compositions comprising a transient
receptor potential cation channel
subfamily V member 1 (TRPV1) receptor
agonist and an antagonist in certain
ratios which allow for the onset of
agonist action followed by alleviation by
antagonist action, and methods of use in
personal defense and law enforcement.
Non-lethal means of temporarily
incapacitating a person are needed for
law enforcement and for personal
protection. A common approach
currently is to use pepper spray.
Although current pepper sprays are
effective, and relatively safe, for most
individuals, they can be life threatening
for people who suffer from asthma and
have hypersensitive airways.
In order to reduce the length of time
the pepper spray can cause the adverse
effects that could result from extended
exposure, inventors at NCI have created
a composition comprising both an
incapacitating pepper spray TRPV1
receptor agonist compound and a
slower-acting TRPV1 receptor
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
61659
antagonist compound that reverses the
effects of the agonist. The agonist/
antagonist composition is intended to be
used as an aerosol or spray, that, when
administered, causes a painful
stimulation and incapacitates a person
for only a short period of time. This
technology may fill a public health need
by improving safety over currently
available pepper sprays.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive license will
be royalty bearing, and the prospective
exclusive license may be granted unless
within fifteen (15) days from the date of
this published notice, the National
Cancer Institute receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public
may file comments or objections.
Comments and objections, other than
those in the form of a license
application, will not be treated
confidentially, and may be made
publicly available.
License applications submitted in
response to this Notice will be
presumed to contain business
confidential information and any release
of information in these license
applications will be made only as
required and upon a request under the
Freedom of Information Act, 5 U.S.C.
552.
Dated: November 9, 2018.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2018–26016 Filed 11–29–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HOMELAND
SECURITY
Federal Emergency Management
Agency
[Docket ID FEMA–2018–0002]
Changes in Flood Hazard
Determinations
Federal Emergency
Management Agency, DHS.
ACTION: Notice.
AGENCY:
New or modified Base (1percent annual chance) Flood
Elevations (BFEs), base flood depths,
Special Flood Hazard Area (SFHA)
boundaries or zone designations, and/or
regulatory floodways (hereinafter
referred to as flood hazard
determinations) as shown on the
SUMMARY:
E:\FR\FM\30NON1.SGM
30NON1
]]>Agencies
[Federal Register Volume 83, Number 231 (Friday, November 30, 2018)]
[Notices]
[Page 61659]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-26016]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Agonist/
Antagonist Compositions and Methods of Use
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Cancer Institute, an institute of the National
Institutes of Health, Department of Health and Human Services, is
contemplating the grant of an Exclusive Patent License to practice the
inventions embodied in the Patents and Patent Applications listed in
the Supplementary Information section of this notice to Bull Run
Capital, Inc. located in Vancouver, BC, Canada.
DATES: Only written comments and/or applications for a license which
are received by the National Cancer Institute's Technology Transfer
Center on or before December 17, 2018 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
and comments relating to the contemplated an Exclusive Patent License
should be directed to: Jaime M. Greene, Senior Licensing and Patenting
Manager, NCI Technology Transfer Center, 9609 Medical Center Drive, RM
1E530 MSC 9702, Bethesda, MD 20892-9702 (for business mail), Rockville,
MD 20850-9702; Telephone: (240) 276-5530; Facsimile: (240) 276-5504;
Email: [email protected].
SUPPLEMENTARY INFORMATION:
Intellectual Property
U.S. Provisional Patent Application No. 61/340,063, filed March 12,
2018, now abandoned, titled ``Agonist/Antagonist Compositions and
Methods of Use'', HHS Ref. No.: E-048-2010-0-US-01;
PCT Patent Application Serial No. PCT/US2011/028132, filed March
11, 2011, now abandoned, HHS Reference Number E-048-2010-0-PCT-02
titled ``Agonist/antagonist compositions and methods of use'';
U.S. Patent 9,277,748 (Application No. 13/634,447) filed March 11,
2011, issued March 8, 2016, titled ``Agonist/antagonist compositions
and methods of use'', HHS Ref. No.: E-048-2010-0-US-04;
Canada Patent Application Serial No. 2,792,878, filed March 11,
2011, HHS Reference Number E-048-2010-0-CA-03 titled ``Agonist/
antagonist compositions and methods of use''; and
U.S. Patent Application Serial No 15/010,830, filed January 29,
2016, HHS Reference Number E-048-2010-0-US-05, titled ``Agonist/
antagonist compositions and methods of use''.
The patent rights in these inventions have been assigned and/or
exclusively licensed to the government of the United States of America.
The prospective exclusive license territory may be worldwide and
the field of use may be limited to: ``Use of the TRVP1 antagonists
BCTC, AMG9810, JYL-827, Capsazepine or IodoRTX combined with a TRVP1
agonist in a composition for the temporary incapacitation of a
subject.''
This technology discloses novel compositions comprising a transient
receptor potential cation channel subfamily V member 1 (TRPV1) receptor
agonist and an antagonist in certain ratios which allow for the onset
of agonist action followed by alleviation by antagonist action, and
methods of use in personal defense and law enforcement.
Non-lethal means of temporarily incapacitating a person are needed
for law enforcement and for personal protection. A common approach
currently is to use pepper spray. Although current pepper sprays are
effective, and relatively safe, for most individuals, they can be life
threatening for people who suffer from asthma and have hypersensitive
airways.
In order to reduce the length of time the pepper spray can cause
the adverse effects that could result from extended exposure, inventors
at NCI have created a composition comprising both an incapacitating
pepper spray TRPV1 receptor agonist compound and a slower-acting TRPV1
receptor antagonist compound that reverses the effects of the agonist.
The agonist/antagonist composition is intended to be used as an aerosol
or spray, that, when administered, causes a painful stimulation and
incapacitates a person for only a short period of time. This technology
may fill a public health need by improving safety over currently
available pepper sprays.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty bearing,
and the prospective exclusive license may be granted unless within
fifteen (15) days from the date of this published notice, the National
Cancer Institute receives written evidence and argument that
establishes that the grant of the license would not be consistent with
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: November 9, 2018.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2018-26016 Filed 11-29-18; 8:45 am]
BILLING CODE 4140-01-P
